Summary A randomized trial to compare adjuvant treatment with an alternating regimen with conventional chemotherapy was performed. A total of 589 node-positive patients were included and stratified according to number of positive nodes (N1-3 and N > 4) and menopausal status. Premenopausal Ni-3 patients were randomized to cyclophosphamide, methotrexate and fluorouracil (CMF) or CMF/4'-epirubicin, cyclophosphamide (EC), post-menopausal N1-3 patients to fluorouracil, 4 epirubicin, cyclophosphamide (FEC) or CMF/EC and pre-and postmenopausal patients with N . 4 to fluorouracil, 4' epirubicin, cyclophosphamide, methotrexate, prednisone (FECMP) or CMF/EC. In premenopausal patients, CMF was superior to CMF/EC in terms of disease-free survival (DFS) (65% vs 45%, P= 0.0149) and survival (72.3% vs 50.2%, P = 0.0220) whereas, for N 2 4 patients, differences between FECMP and CMF/EC did not achieve statistical significance (DFS 35% vs 26.2%; survival 50% vs 38.1%, P = NS). For post-menopausal patients, FEC was superior to CMF/EC in DFS (58.6% vs 36.8%, P = 0.0215) and survival (66.2% vs 46%, P = 0.0155). In post-menopausal patients with N > 4, differences favouring CMF/EC were significant in DFS (40.4% vs 22%, P = 0.0371) but not in survival (47.4% vs 32.2%, P = 0.1185). Alternating regimens did not offer better results in premenopausal and post-menopausal N1-3 patients. Results regarding post-menopausal N > 4 women require further confirmation.
Adjuvant chemotherapy reduces the risk of recurrence and death in almost all prognostic groups of women with breast cancer (EBCTCG, 1992) . However, overall outcomes remain to be improved, especially for node-positive patients. Attempts to achieve better survival rates include the administration of new agents, dose intensification and strategies to overcome or prevent drug resistance. Goldie and Coldman's hypothesis states that drugresistant clones could emerge from mutations produced before or early during chemotherapy administration (Goldie and Coldman, 1979) . This model emphasizes the importance of applying as many effective drugs as possible in the shortest time interval. Alternating non-cross-resistant regimens were tested in several clinical models but, except for meclorethamine oncorin-procarbanin-prednisoneadriamycin bleomycin rinblastine DTIC (MOPP-ABVD) vs MOPP in advanced Hodgkin's disease (Bonadonna et al, 1986) , their superiority to standard treatment has not been demonstrated.
This trial was designed during the early 1980s to compare 4' epirubicin standard regimens with the alternation of cyclophosphamide, methotrexate, fluorouracill4' epirubicin, cyclophosphamide (CMF/EC) in node-positive women with breast cancer. Although the CMF regimen is considered to be standard treatment for premenopausal patients with one to three positive axillary nodes, outcomes for patients with more than four nodes, as well as for post-menopausal women, are still suboptimal. Consequently, anthracycline-based schemes were used in these subsets. Likewise, the combination of 4' epirubicin and cyclophosphamide has been chosen because of its efficacy in advanced disease and the theoretical lack of complete cross-resistance with the CMF regimen.
PATIENTS AND METHODS Patients
Between July 1985 and July 1987, 589 consecutive women with histologically confirmed axillary node-positive breast cancer were included in this trial. Twenty-one patients were removed from the study because of major violations of inclusion criteria, treatment administration and lack of adequate follow-up data. Surgical procedures included modified radical mastectomy, quadrantectomy or tumorectomy (with uninvolved margins) plus axillary node dissection.
Patients were excluded from the study if they had clinical evidence of metastasis, were aged > 75 years or had a documented history of previous cancer (except surgically treated basal cell carcinoma of the skin or early cervical carcinoma) or any systemic condition precluding proper administration of chemotherapy. Histological analyses of more than ten axillary lymph nodes were required. Patients must have been included within 6 weeks from surgery.
Patients' characteristics (Tables 1 and 2) were homogeneously distributed across treatment arms. During the inclusion period, the technology for hormonal receptor assays was not available in many centres throughout the country, and thus receptor status was unknown for most patients (more than 70%). The high frequency of T2 tumours (80%) and patients undergoing mastectomy (70%) is also noteworthy. Treatment regimens
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Patients were randomly assigned to one of two regimens according to their menopausal status and number of positive axillary nodes ( Figure 1 ). Post-menopausal status was defined by the absence of menses during the last year. Treatment regimens are presented in Table 3 . Radiation therapy was administered to patients with conservative surgery during or after chemotherapy. No dose reduction was allowed. For patients with granulocyte counts less than 1500 mm-3or platelet counts less than 100 000 mm3, chemotherapy was delayed for 1 or 2 weeks. If no haematological recovery was observed at that time, the patient was removed from study. Toxicity was recorded according to the WHO toxicity criteria. This protocol was approved by the human investigation committees of the participating institutions. any cause or to last follow-up, measured from time to entry to the protocol. Survival is defined as the time to death from any cause or to last follow-up, measured from time to entry to the protocol. Differences in the distribution of patients' characteristics across menopausal status were assessed using the exact test for contingency tables. Disease-free survival and survival distribution were estimated using the product limit method of Kaplan and Meier (Kaplan and Meier, 1958) . The statistical significance of differences observed in the distribution of time to events was assessed using the log-rank test (Peto et al, 1977) . All P-values reported are two sided.
RESULTS
Disease-free survival and survival (Table 5) Premenopausal patients
Comparison between CMF and CMF/EC in patients with 1-3 positive nodes disclosed statistically significant differences in DFS, in favour of CMF (log-rank test P = 0.015), with estimated 8-years DFS being 65% with CMF (95% CI 51-76%) vs 45% (95% CI 32-58%) with CMF/EC. These differences were also apparent for survival (P = 0.0220), with estimated 8-year survival of 72.3% (95% CI 59-82%) vs 50.2% (36-66%) with CMF and CMF/EC respectively. Figure 2A and B discloses survival curves for both treatment arms. A median DFS of 49 months for patients in the CMF/EC arm was observed, whereas the median for CMF patients has not yet been reached. On the other hand, in patients with more than four positive lymph nodes, CMF/EC has not produced better outcomes than FECMP neither in DFS (log-rank test P = 0.3160) with estimated 8-year DFS of 26.2% (95% CI 14-40%) with CMF/EC and 35% with FECMP (95% CI 21-49%) ( Figure 2C ) nor in survival (P = 0.2879) with estimated 8-year survival of 38.1% (95% CI 24-52%) vs 50% (95% CI 36-62.5%) ( Figure 2D ). This lack of difference persisted even when data were analysed for different positive node strata (4-7 and > 8) (data not shown). Median DFS and survival in patients treated with CMF/EC were shorter than those with FECMP (60 and 83 months vs 77 and 96 months respectively).
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In the subset with one to three positive nodes, patients randomized to FEC did better than those in the CMF/EC arm (log-rank test for DFS P = 0.0215), achieving a better estimated 8-year DFS -58.6% for FEC (95% CI 47-69%) vs 36.8% for the alternating scheme (95% CI 25-49%) (Table 5) . Median DFS was 71 months for CMF/EC. Median DFS has not been reached for patients receiving FEC ( Figure 3A ). Differences in survival were also significant (P = 0.0155), with estimated 8-year survival of 66.2% (95% CI 54-76%) for FEC vs 46% (95% CI 33-58%) CMF/EC; and the median survival for the FEC group was 25 months longer than that for the CMF/EC group (116 vs 91 months) ( Figure 3B ). Regarding patients with more than four lymph nodes, unexpected differences favouring the alternating chemotherapy group were observed in DFS (P = 0.0371). Estimated 8-year DFS was 40.4% (95% CI 29-51%) with CMF/EC vs 22% (95% CI 13-32%) for FECMP; whereas survival figures have reached no statistical significance (P = 0.1185), with estimated 8-year survival of 47.4% (95% CI 36-58%) vs 32.2% (95% CI 22-43%) respectively ( Figure 3C and D) . These results are not related to distribution of prognostic factors, such as number of positive nodes or tumour size, as these variables were homogeneously distributed across treatment arms.
Major sites of first relapse of disease were bone (18.2-31%), skin (9.3-16.7%), liver (8.1-17.6%) and lung (5-16.3%) as well as multiple metastatic involvement (15-33.1%). Multiple metastatic involvement as the first manifestation of recurrence was more frequently observed in premenopausal than in post-menopausal patients (24.3% vs 16.7%). No other differences were found when the pattern of relapse was analysed in relation to menopausal status, nodal groups and chemotherapy regimens.
Toxicity
Information about toxicity is shown in Table 6 . No patient required hospitalization for toxic complications. No platelet or red cell transfusions were administered. The most frequently reported side-effects were emesis and alopecia. The percentage of courses complicated with grade 3-4 emesis was slightly higher in the anthracycline-containing regimens. The alternating regimen was not less toxic than FECMP or FEC as long as anthracycline-related alopecia was considered (76.6% for CMF/EC vs 85.1% and 80% for FEC and FECMP respectively, P = 0.3634). No case of clinically overt congestive heart failure was observed.
Two treatment-related deaths were reported. The first patient developed liver failure during CMF treatment, while the second patient suffered sudden death during FEC chemotherapy. Twelve further patients died without evidence of relapse months to years after completing chemotherapy. Information about causes of death was obtained from clinical reports as autopsy was not performed in British Journal of Cancer (1997) 76(4) 
DISCUSSION
Goldie and Coldman's (1979) hypothesis, which is challenged by this study, emphasizes the possibility of overcoming drug resistance by the administration of non-cross-resistant chemotherapeutic regimens. This assumption was based on a mathematical model as well as on experimental and early clinical observations regarding advanced Hodgkin's disease and small-cell lung cancer (Evans et al, 1987) . Our results in patients with one to three positive axillary nodes suggest that six full cycles of CMF in premenopausal or FEC in post-menopausal women are superior to the administration of CMF/EC regimen for both DFS (Spittle et al, 1987; Budzar et al, 1988; Falkson et al, 1991; Bonadonna et al, 1995) . Conversely, results from the ECOG (Tormey et al, 1992) showed prolonged DFS in patients receiving alternating chemohormonotherapy in the adjuvant setting, although the use of hormonal manipulation obscures the interpretation of data.
British Journal of Cancer (1997) On the other hand, for patients with more than four positive lymph nodes, results diverge depending on menopausal status. For younger patients, a trend favouring FECMP did not reach statistical significance. This effect could reflect the actual lack of difference or type II error related to the low statistical power of the sample.
Findings regarding the superiority of CMF/EC in postmenopausal patients deserve separate consideration. Although dose intensity seems to be one of the -if not the most -important features of breast cancer regimens, the relative contribution of each drug to the final outcome is still unknown. In respect to that mentioned above, it is likely that FECMP does not fit the requirements of an adequate regimen for dose intensity purposes (see Table 4 ). Noteworthy are the results reported by Peters et al (1994) about the critical importance of 5-FU dose intensity. Furthermore, differences in pre-and post-menopausal tumour biology may account for the apparent superiority of a non-cross-resistant regimen as they do for the lower benefit from chemotherapy reported for older women (EBCTCG, 1992) .
Recent reports have raised the concern of anthracycline-related carcinogenesis. It is noteworthy that no case of treatment-related leukaemia has been observed among these more than 500 women with a median follow-up of 8 years. Likewise no report of cumulative cardiomyopathy was registered, confirming the low frequency of such a complication in the current adjuvant setting (Chacon et al, 1992) .
In summary, our results suggest that alternating regimens offer no advantage or even can compromise critical end points in preand post-menopausal women with one to three positive axillary nodes and premenopausal patients with more than four nodes. The benefits of CMF/EC in post-menopausal patients with more than four positive nodes require further confirmation.
